• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Humacyte Inc (NQ: HUMA )

    7.735 -0.435 (-5.32%)
    Official Closing Price Updated: 4:15 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,998,269
    Open 8.254
    Bid (Size) 7.750 (1)
    Ask (Size) 7.870 (23)
    Prev. Close 8.170
    Today's Range 7.650 - 8.490
    52wk Range 1.960 - 9.970
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Three Small-Cap Stocks to Buy Before a September-Rate-Cut Rally
    Discover three small-cap stocks to buy before the Fed acts on interest rates as these small-cap stocks will utilize any cuts to multiply. 
    Via InvestorPlace
    Topics Economy
    Exposures Interest Rates
    What's Going On With Huamacyte Shares Tuesday?
    Humacyte has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement with Pluristyx and received Regenerative Medicine Advanced Therapy (RMAT)... 
    Via Benzinga
    Exposures Product Safety

    Performance

    YTD
    +167.65%
    +167.65%
    1 Month
    +30.33%
    +30.33%
    3 Month
    +115.46%
    +115.46%
    6 Month
    +198.65%
    +198.65%
    1 Year
    +147.12%
    +147.12%

    More News

    Read More
    Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    (HUMA) - Analyzing Humacyte's Short Interest
    Via Benzinga
    Peering Into Humacyte's Recent Short Interest
    Via Benzinga
    How Is The Market Feeling About Humacyte?
    Via Benzinga
    Peering Into Humacyte's Recent Short Interest
    Via Benzinga
    MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
    From Pluristyx
    Via Business Wire
    Why Humacyte Stock Is Trading 15% Higher Monday
    Via Benzinga
    Tommy Tuberville Sells Several Large Stock Positions, Makes New Buys: Here's What The US Senator Is Betting On Now
    Via Benzinga
    HUMA Stock Earnings: Humacyte Meets EPS for Q4 2023
    Via InvestorPlace
    Earnings Preview: Humacyte
    Via Benzinga
    AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Why American Eagle Outfitters Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    HUMA Stock Earnings: Humacyte Misses EPS for Q1 2024
    Via InvestorPlace
    Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Tommy Tuberville Trades Raise Eyebrows Again: Senator Sells Put Options, Buys Small Biotech Linked To Ukraine-Russia War
    Via Benzinga
    Earnings Scheduled For March 22, 2024
    Via Benzinga
    Investor Optimism Improves Slightly; Dow Jumps Over 250 Points
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Senator Tommy Tuberville's Latest 2 Stock Trades Attract The Wrong Kind Of Attention: 'Should This Be Allowed?'
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.